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Abstract
Background: The effects of HAART may differ between children and adults because children have
a developing immune system, and the long-term immunological outcome in HIV-infected children
on HAART is not well-known. A major aim of our study was to determine CD4+ evolution
associated with long-term VL control during 4 years of observation on HAART.
Methods: We carried out a retrospective study on a cohort of 160 vertically HIV-infected
children. It was carried out from 1996 to 2004 in six large Spanish pediatric referral hospitals. We
compared 33 children who had long-term VL suppression (VL ≤400 copies/ml) in the first 12
months of follow-up and maintained that level throughout follow-up (Responders-group), and 127
children with persistently detectable VL in spite of ART switches (Non-Responders-group).
Results: We observed a quick initial and significant increase in CD4+ counts from the baseline to
12 months on HAART in both groups (p < 0.01). The Non-Responders group sustained CD4+
increases and most of these children maintained high CD4+ level counts (≥25%). The Non-
Responders group reached a plateau between 26% and 27% CD4+ at the first 12 months of follow-
up that remained stable during the following 3 years. However, the Responders group reached a
plateau between 30% and 32% CD4+ at 24, 36 and 48 months of follow-up. We found that the
Responders group had higher CD4+ count values and higher percentages of children with CD4+ ≥25%
than the Non-Responders group (p < 0.05) after month 12.
Conclusion: Long-term VL suppression in turn induces large beneficial effects in immunological
responses. However, it is not indispensable to recover CD4+ levels.
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Background
The efficacy of highly active antiretroviral therapy
(HAART) is shown by the fact that many patients achieve
suppression of viral load (VL) below the limits of detec-
tion (uVL) along with an increase of CD4+ T-lymphocytes
(CD4+) [1,2], resulting in a good clinical outcome [3,4].
Immediate suppression of VL is often achieved with
HAART, but long-term suppression of VL is not always fea-
sible [1]. Children receiving treatment usually have higher
VL and lower virologic response rates than adults [1,5].
Moreover, the effects of HAART may differ between chil-
dren and adults because children have a developing
immune system, but the long-term immunological out-
come in HIV-infected children on HAART is not well-
known [6]. A major aim of our study was to determine
CD4+ evolution associated with long-term VL control.
Methods
Population and study design
A retrospective study on a cohort of 160 vertically HIV-
infected children has been carried out from 1996 to 2004
in six large Spanish pediatric referral hospitals. The inclu-
sion criteria of HIV-1-infected children were the follow-
ing: a) starting HAART with protease inhibitor (PI) or
non-nucleoside analogue HIV-1 reverse transcriptase
inhibitor (NNRTI); b) 4 years of follow-up after starting
HAART; c) VL >5,000 copies/ml at entry to the study, d)
older than 6 months of age at entry. From an initial cohort
of 200 vertically HIV-1-infected children with at least 4
years on HAART, 40 children were excluded because they
had VL <5,000 copies/ml (30 children), no data regarding
VL (1 child), or they were less than 6 months old (9 chil-
dren). Therefore, 160 out 200 HIV-infected children ful-
filled the criteria of inclusion and were enrolled in the
present retrospective study.
This study was approved by the Ethical Committees of all
hospitals involved. Clinical classification was based on
the 1994 revised guidelines of the Centers for Disease
Control (CDC). The children were monitored at least
every 3 months with repeated interviews, physical exami-
nations, and blood sample collection. There was not an
uniform approach regarding antiretroviral treatment.
Instead, each pediatrician administered the appropriate
antiretroviral therapy (ART) regimen and changed the
drugs according to his/her interpretation of the child's
data and following international guidelines. The adher-
ence of antiretroviral drugs was measured by each pedia-
Table 1: Characteristics of clinical, immunological, and virological parameters of vertically HIV-1-infected children.
Responders Non-Responders
N. of HIV-infected children 33 127
Age (years) (a) 5.9 (1.2; 15.7) 5.7 (0.5; 14.9)
Male (b) 17 (51.5%) 58 (45.6%)
AIDS diagnosis (CDC) (b) 13 (39.3%) 58 (45.6%)
Current immunological category (b)
> 25% CD4+ 8 (24.2%) 40 (31.4%)
15% – 25% CD4+ 9 (27.2%) 31 (24.4%)
< 15% CD4+ 16 (48.4%) 52 (40.9%)
Immunological parameters (a)
% CD4+ 12 (0.1; 35) 18 (0.1; 52)
CD4+/µL 333 (4; 1207) 440 (1; 2620)
% CD8+ 49 (22.1; 82) 47 (13; 74.6)
CD8+/µL 927 (238; 3763) 1006 (17; 6466)
Virological characteristics
log10 VL (copies/mL) (a) 4.8 (3.7;6.4) 4.8 (3.7; 6.5)
VL ≤10,000 copies/mL (b) 6 (18.1%) 8 (6.2%)
VL 10,000 to 30,000 copies/mL (b) 7 (21.2%) 28 (22.1%)
VL 30,000 to 100,000 copies/mL (b) 11 (33.3%) 35 (27.5%)
VL >100,000 copies/mL (b) 9 (27.2%) 56 (44.1%)
ART prior to HAART
ART-naïve HIV-infected children (b) 13 (39.4%) 17 (13.4%)*
HIV-infected children with previous ART (b)
Monotherapy 15 (45.4%) 71 (55.9%)
Combined Therapy 18 (54.5%) 99 (77.9%)*
Monotherapy + Combined Therapy 20 (60.6%) 110 (86.6%)*
Time (months) with previous ART (a) 25.9 (0; 75.8) 22.4 (0; 114.1)
Previous ART-protocol switches (a) 2 (0; 4) 2 (0; 5)
Values are expressed as: a) median (min; max), and b) absolute (percentage). VL: viral load; CDC = Center for Disease Control. VL: viral load. 
Differences between groups (*: p < 0.01).BMC Infectious Diseases 2006, 6:10 http://www.biomedcentral.com/1471-2334/6/10
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trician by examination of the dose taken by each child and
through interviews with his parents or tutors.
Response to long-term HAART
A completed long-term virological response to HAART
was defined when HIV-child achieved undetectable VL
(≤400 copies/ml) in the first 12 months of therapy and
maintained that level during at least 12 months. Thus,
HIV-infected children were divided into two groups
according to responses to long-term HAART:
a) Responders group
33 HIV-infected children with a full long-term virological
response during at least 12 months. Detectable VL during
a 12 months period, even if a small "blip", disqualified
children from being included in the Responders group.
Moreover, 29 of 33 had full long-term virological
response during at least 24 months, and 25 of 33 had full
long-term virological response during at least 36 months.
b) Non-Responders group
127 HIV-infected children with persistently VL despite
HAART (VL ≥400 copies/ml during follow-up). These
HIV-infected children had prolonged virological failure in
spite of ART switches.
HIV-1 infection laboratory markers
T-lymphocyte subsets in peripheral blood were quantified
by flow cytometry (FACScan, Becton-Dickinson Immuno-
cytometry Systems, San Jose, CA, USA). VL was measured
in 200 µl plasma samples using a quantitative assay
(Amplicor monitor, Roche Diagnostic Systems, Branden-
burg, NJ, USA).
Statistical analysis
We analyzed the CD4+ at 0, 12, 24, 36, and 48 months fol-
low-up of children on HAART grouped according to
response to long-term virological suppression with a Gen-
eral Lineal Model (GLM) Univariate (regression analysis)
adjusted by baseline characteristics (age, sex, ART-naïve,
CD4+, and VL). In addition, we analyzed immunological
response to HAART in HIV-infected children (CD4+ >25%
at 12, 24, 36, 48 months follow-up) by logistic regression.
Results
At baseline (before starting HAART), the two groups had
similar age, percentage in clinical category C, levels of
CD4+ and CD8+ T-cells, and VL (Table 1). However, the
Non-Responders group had a higher percentage of the
pre-treatment with ART.
During follow-up, one child progressed to AIDS and one
child died. Moreover, the Non-Responders group presented
a significantly higher number of ART switches, higher
number of different drugs used in ART than children of
the Responders group (p ≤ 0.05) (Table 1).
Long-term viral load suppression was achieved in only
about 20% of followed children. This low figure is mostly
related to poor adherence by the non-responders group
(48% vs 91% in responders) (Table 1). There were not sig-
nificant differences in adherence according to hospital
and region involved.
Table 2 shows the first line HAART schemes. We did not
find significant differences in PI used in first line HAART
between groups. Moreover, there were 3320 VL assays per-
Table 2: Characteristics of antiretroviral treatment and virologic parameters of vertically HIV-1-infected children during follow-up.
Responders Non-Responders
HAART during follow-up
NNRTI or PI in first-line of HAART (b)
Ritonavir 4 (12.1%) 32 (25.1%)
Saquinavir 6 (18.2%) 12 (9.4%)
Indinavir 8 (24.2%) 28 (22.1%)
Nelfinavir 10 (30.3%) 44 (34.6%)
Amprenavir 3 (9.1%) 5 (3.9%)
Nevirapina 0 (0%) 6 (4.7%)
Efavirenz 6 (18.1%) 10 (7.8%)
ART-protocols switches (a) 1 (0; 4) 1 (0; 11) *
Drugs switches (a) 1 (0;7) 3 (0;12) *
Adherence >95% (b) 30 (90.9%) 61 (48%) *
VL tests
Total VL tests (a) 20 (6; 34) 21 (3; 48)
Number of tests with VL ≤400 copies/mL (a) 15 (5; 28) 3 (0; 23) *
Time to first uVL measure (a) 3.7 (0.2; 12) 29.4 (0.9; 59.8) *
Time to last uVL measure (a) 49.8 (16.1; 59.6) 57.5 (31.8; 60) *
Values are expressed as: a) median (min; max), and b) absolute (percentage). ART: antiretroviral therapy; VL: viral load; PI: protease inhibitor; 
NNRTI. Differences between groups (*: p < 0.01).BMC Infectious Diseases 2006, 6:10 http://www.biomedcentral.com/1471-2334/6/10
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formed on samples obtained from HIV-infected children
during the 4 years of follow-up; 1054 (47.3%) of those
did not reach the lower limit of detection of 400 HIV-RNA
copies/mL. The VL tests performed were similar for the
two groups, but the Responders group had a higher
number of tests with VL ≤400 copies/ml. Moreover, the
median of time between the first and last VL ≤400 copies/
ml measurement was lower in the Responder group than
the Non-responder group (Table 2). The Responders
group had uVL after the 1st year on HAART and the Non-
Responders group had a low decrease of VL during the 4
years of follow-up (Figure 1A). Furthermore, the Respond-
ers group had a higher percentage of children with CD4+
>30% than the Non-Responders group after 1st year on
HAART (Figure 1B).
Table 3 shows the mean of %CD4+ and percentage of HIV-
infected children with CD4+ ≥25% during the 4 years of
follow-up stratified by virological response to HAART. We
observed an initial and significant fast increase in CD4+
counts from baseline to 12 months on HAART in both
groups (p < 0.01). Interestingly, there were children on
HAART with sustained CD4+ increases but with detecta-
ble VL. Non-Responders group was sustained CD4+
increases and most of theses HIV-infected children main-
tained high CD4+ level counts (≥25%). The Non-Respond-
ers group also reached a plateau between 26% and 27%
CD4+ at 12 months of follow-up that remained stable dur-
ing the following 3 years (Table 3). However, the Respond-
ers group reached a plateau between 30% and 32% CD4+
at 24, 36 and 48 months of follow-up. We found that the
Responders group had higher CD4+ count values and a
higher percentage of children with CD4+ ≥25% than the
Non-Responders group (p < 0.05) after month 12 (Table 3).
Discussion
The introduction of HAART represented a major break-
through in the therapeutics of HIV-infected patients.
However, the overall effectiveness of long-term HAART on
HIV-infected children has been scarcely studied. Thus, to
date, few studies reflect the evolution of a large cohort of
HIV-infected children throughout long-term HAART [6].
To analyze this, we recruited a large group of HIV-infected
children starting HAART and tracked their progress for 4
years. Our retrospective longitudinal study provides evi-
Evolution of mean plasma log10 VL (A) and percentage of  HIV-infected children with CD4+ >30% (B) grouped by long- term VL suppression (Responders vs. Non-Responders) Figure 1
Evolution of mean plasma log10 VL (A) and percentage of 
HIV-infected children with CD4+ >30% (B) grouped by long-
term VL suppression (Responders vs. Non-Responders). an: 
number of children in the Responders group. bn: number of 
children in the Non-Responders group. Differences between 
groups (*: p < 0.01).
Table 3: Summary of %CD4+ T-cell and percentages of HIV-infected children having CD4+ ≥25% at 0, 12, 24, 36, and 48 months of 
follow-up stratified by long-term virological response to HAART. The groups were compared by General Lineal Model and Logistic 
Regression analysis adjusted.
CD4+ T-cells (%) Percentage of children with CD4+ ≥25%
Follow-up n. Responders n. Non-
Responders
pR e s p o n d e r s N o n -
Responders
OR (CI95%) p
0 months 33 16.4 ± 1.9 123 18.7 ± 1.2 0.190 24.2% 31.4% 0.6 (0.2; 1.6) 0.372
12 months 31 27.5 ± 1.7 121 26.2 ± 0.2 0.145 64.5% 53.7% 2.6 (0.9; 7.3) 0.071
24 months 31 29.5 ± 1.3 115 27.2 ± 0.9 0.010 70.9% 57.4% 3.1 (1.1; 8.6) 0.031
36 months 30 31 ± 1.2 109 27.7 ± 0.9 0.005 83.3% 62.3% 4.4 (1.4; 13.6) 0.009
48 months 28 32.1 ± 1.3 97 27.9 ± 1 0.004 85.7% 62.8% 5.4 (1.5; 18.9) 0.008
OR: odd ratio; CI95%: confidence interval of 95%; p: level of significance.BMC Infectious Diseases 2006, 6:10 http://www.biomedcentral.com/1471-2334/6/10
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dence from current clinical practice that HAART always
show long-term sustained uVL only in a low proportion of
children (20.6%) just as it has previously been showing in
published results in adults [7].
CD4+ recovery despite virological failure has been referred
to as discordant responses and this phenomenon has
been observed in children [8]. However, in children on
HAART, levels of CD4+ recovery were not comparable for
virological responders and non-responders, indicating
that CD4+ recovery during virological suppression is more
profound than during virological failure [8]. This may
reflect the inhibitory effect of HIV on thymic function
since a marked decrease or suppression in VL is necessary
to allow the thymus to replenish the CD4+ T-cells. Moreo-
ver, CD4+ T-cells are productively infected by HIV, under-
going apoptosis induced by abnormal cellular activation
when the VL is not controlled [9].
In children with virological failure and good immunolog-
ical and clinical outcomes observations have that virolog-
ical failure does not always equal clinical failure [10,11].
Others authors have suggested that in children VL sup-
pression may not be the best way to clinically evaluate
ART success as it seem to be for HIV-infected adults [7].
Addition, HIV-infected children on HAART usually have
higher VL and lower virological response rates than adults
[12]. Thus, maintaining constant or improving CD4+
counts may represent alternative indices of ART success in
children [13]. We found an increase of CD4+ counts in the
Responders and the Non-Responders groups. This indicates
that VL suppression was not indispensable to the recovery
of the immune system in vertically HIV-infected children.
Moreover, only one Non-Responders child died during fol-
low-up and another evolved to AIDS. We carried out indi-
rect measurement between responders and non-
responders (hospitalization rates, weight/height growth
curves, and numbers of opportunistic infections), and we
found an improvement in these indices but not find dif-
ferences between groups (data not shown). Therefore, viro-
logical failure does not always equal clinical failure and
virological suppression does not necessarily mean proper
function. However, long-term suppression of VL allowed
higher values of CD4+ counts.
High VL is associated with immune system activation
which is used as a predictive marker of virologic failure
[14,15]. Moreover, viral suppression is a powerful predic-
tor of CD4+ increase [16]. About 30% of HIV-infected
adults receiving HAART exhibit a sustained CD4+ increase
despite therapy failure, or they have persistently low CD4+
counts despite a significant decrease in VL [17]. In this
study, approximately 30% of HIV-infected children also
had an increase of CD4+ to a level ≥25% at 24 (57.39%-
35.52%), 36 (62.38%-35.52%), and 48 (62.88%-
35.52%) months.
The capacity for CD4+  regeneration during long-term
HAART has not been well defined. In our study, children
reached a plateau in CD4+ cell after 2 years on HAART just
as others authors have published results in adults [18,19].
Moreover, Hunt et al. present strong evidence that CD4+
counts continue to increase up to 4 years after HAART
[20]. However, the rate of CD4+ recovery in adults is slow
and a steady state is not usually reached after 4 years most
likely because the adult thymus is less functional than in
children [21].
A limitation of our study was that we did not have viro-
logic resistance data previous to HAART and during fol-
low-up. Increasingly many clinicians and investigators are
describing multi-drug resistant HIV among children who
are extensively HAART experienced [22]. Moreover, high
baseline VL and substantial but imperfect levels of adher-
ence were associated with HIV-resistance [23] and may
facilitate an earlier virological failure [22]. Therefore,
adherence to medication is extremely important and may
have a significant, effect unaccounted for in the interpre-
tation of our results. All efforts were made by health per-
sonnel to improve adherence in each child. Traditionally,
children's adherence to ART has been limited, even
though response to therapy has been shown to be highly
dependent on the patient's adherence [24,25]. In this
study, the adherence to ART was not strictly monitored, as
opposed to standard clinical trials. We also found that
adherence to ART was the most important variable associ-
ated with long-term VL suppression (data not shown).
However, therapy adherence is almost impossible to reli-
ably measure, and accurately reproduce in a long-term
dynamic cohort [7]. This low adherence in the Non-
Responders  group is not related to the level of training
received by the health personal who provided the medical
care. Furthermore, the number of doctor visits was similar
in both groups of children, but the Responders group had
a higher number of tests with VL ≤400 copies/mL and a
lower time with the first uVL measurement than the Non-
Responders group.
Conclusion
In conclusion, long-term VL suppression induces large
beneficial effects in immunological responses. However,
it is not indispensable to recover CD4+ counts (levels).
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